Get started
Author

Khodayar Farahmand

Observed names: Farahmand Khodayar, K. Farahmand
OpenAlex ID: A5113065584
The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder
2018 · Roger S. McIntyre, Joseph R. Calabrese, et al. · Journal of Affective Disorders · 14
PDF
Utility and limitations of the FDA adverse events reporting system public dashboard for safety analyses: a case study with vesicular monoamine transporter 2 inhibitors
2025 · Roger S. McIntyre, Shree Karpuram, et al. · Expert Opinion on Drug Safety · 11
PDF
The effects of valbenazine on tardive dyskinesia in older and younger patients
2019 · Martha Sajatovic, George S. Alexopoulos, et al. · International Journal of Geriatric Psychiatry · 10
PDF
VMAT2 inhibitors for the treatment of tardive dyskinesia: a narrative review
2025 · Amita R. Patel, Robert A. Hauser, et al. · CNS Spectrums · 8
PDF
Nighttime and morning OFF improvements with opicapone in patients with Parkinson's Disease and motor fluctuations: BIPARK-1 and BIPARK-2 pooled subanalyses
2020 · R.A. Hauser, M.F. Lew, et al. · Parkinsonism & Related Disorders · 2
123 Long-Term Outcomes with Valbenazine 40 mg/day in Adults With Tardive Dyskinesia
2020 · Craig Chepke, Stephen R. Marder, et al. · CNS Spectrums · 2
PDF
Effects of Long-term Valbenazine in Kinect 4: Post Hoc Response and Shift Analyses in Younger and Older Adults With Tardive Dyskinesia
2020 · Martha Sajatovic, George Alexopoulos, et al. · American Journal of Geriatric Psychiatry · 2
Efficacy of Opicapone Compared to Entacapone in Parkinson’s Patients with Motor Fluctuations and ON Hoehn & Yahr ≤ 2.5: A Post Hoc Analysis of BIPARK-1 (4429)
2020 · Mark Lew, Robert Hauser, et al. · Neurology · 1
Effects of Long-Term Valbenazine on Tardive Dyskinesia and Patient-Reported Outcomes: Results from the KINECT 4 Study (P4.078)
2018 · Stewart Factor, John Kane, et al. · Neurology · 1
Long-Term Safety and Tolerability of Valbenazine in Older and Younger Adults with Tardive Dyskinesia
2018 · Martha Sajatovic, George S. Alexopoulos, et al. · American Journal of Geriatric Psychiatry · 1
Prevalence of dysphagia among patients with Huntington’s disease: a literature review
2025 · F. Amjad, S. Hinton, et al. · Parkinsonism & Related Disorders
Patients with dysphagia have multiple options for taking once-daily valbenazine to treat tardive dyskinesia or chorea associated with Huntington’s disease
2025 · R. Jimenez, M. Hebert, et al. · Parkinsonism & Related Disorders
Remission of Tardive Dyskinesia in Patients Receiving Long-Term Valbenazine Treatment
2025 · L. Bahroo, A.J. Cutler, et al. · Parkinsonism & Related Disorders
Efficacy of opicapone in Parkinson's patients with motor fluctuations and ON Hoehn & Yahr ≤2.5: post hoc analysis of BIPARK-1
2020 · M.F. Lew, R.A. Hauser, et al. · Parkinsonism & Related Disorders
Long-term treatment with valbenazine 40 mg once-daily in adults with Tardive dyskinesia
2020 · C. Chepke, S.R. Marder, et al. · Parkinsonism & Related Disorders
Real-world evaluation of patient characteristics and disease management in long-term valbenazine treatment in adults with Tardive dyskinesia
2020 · S. Siegert, C. Yonan, et al. · Parkinsonism & Related Disorders
Treatment Responses with Long-Term Valbenazine in Patients with Tardive Dyskinesia (1663)
2020 · Carlos Singer, Cynthia Comella, et al. · Neurology
140 Effects of Long-Term Valbenazine on Tardive Dyskinesia in KINECT 4: Post Hoc Response and Shift Analyses
2020 · Stephen R. Marder, Cynthia L. Comella, et al. · CNS Spectrums
PDF
139 Early Response with Valbenazine and Long-Term Symptom Reduction in Patients with Tardive Dyskinesia: Post Hoc Analysis of the KINECT 3 Study
2020 · Stanley N. Caroff, Jean-Pierre Lindenmayer, et al. · CNS Spectrums
PDF
Once-Daily Opicapone Increases ON-Time in Patients with Parkinson’s Disease: Results from Two Phase 3 Studies (S4.003)
2019 · Peter LeWitt, Daniel Claassen, et al. · Neurology
Effects of Concomitant Medication Use on Tardive Dyskinesia Outcomes in Long-Term Valbenazine Trials (P4.8-035)
2019 · Cynthia Comella, Carlos Singer, et al. · Neurology
O12.6. Long-term Effects of Valbenazine on Tardive Dyskinesia in Patients With Schizophrenia/schizoaffective Disorder: Results From an Open-label, Rollover Study
2019 · John Kane, Stephen Marder, et al. · Schizophrenia Bulletin
PDF
Safety Results From 3 Long-term Valbenazine Studies in Younger and Older Adults With Tardive Dyskinesia
2019 · George Alexopoulos, Martha Sajatovic, et al. · American Journal of Geriatric Psychiatry
Global Improvements in Tardive Dyskinesia and Patient Satisfaction With Valbenazine in Older and Younger Patients: Results From an Open-label, Rollover Study
2019 · Martha Sajatovic, Jean-Pierre Lindenmayer, et al. · American Journal of Geriatric Psychiatry
67 Effects of Long-term Valbenazine on Psychiatric Status in Patients with Tardive Dyskinesia and a Primary Mood Disorder
2019 · Roger S. McIntyre, Gary Remington, et al. · CNS Spectrums
PDF
Works count: 30
Citation count: 52
H-index: 4
I10-index: 3
Year
Topic
Type